Thomas v. Scalia. That's a new one. The AP reports that "Court Rules in Favor of MedImmune."From the article: "MedImmune 'assuredly did contend that it had no obligation under the license to pay royalties on an invalid patent,' Scalia wrote. 'Promising to pay royalties on patents that have not been held invalid does not amount to a promise' not to contest the matter."